Following validation of the assay using cases of lung adenocarcinoma with known gene rearrangements involving ALK, ROS1, RET, and MET exon 14 skipping mutations, we identified a MET exon 14 skipping mutation in one NGS-negative case and ALK expression imbalance in another, of which the MET exon 14 skipping mutation was subsequently confirmed by WES/WTS NGS via a commercial assay. Here, MET is linked to lung adenocarcinoma.